Rankings
▼
Calendar
ABCL (AbCellera Biologics Inc.) Stock Financials & Earnings | Market Cap Arena
ABCL
AbCellera Biologics Inc.
Mkt Cap
$1B
Healthcare
·
Biotechnology
·
🇨🇦 Canada
·
NASDAQ
Revenue (TTM)
$75M
Net Income (TTM)
-$146M
EPS (TTM)
-$0.49
Free Cash Flow (TTM)
-$174M
Gross Margin
100.0%
Op. Margin
-289.0%
Net Margin
-194.9%
FCF Margin
-231.7%
P/S Ratio (TTM)
14.6x
P/E Ratio (TTM)
—
YoY Rev Growth
+160.6%
Employees
—
Earnings Reports
▶
Q4 2025
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$12M
$12M
-$65M
Q2 23
$10M
$10M
-$51M
Q3 23
$7M
$7M
-$55M
Q4 23
$9M
$9M
-$66M
Q1 24
$10M
$10M
-$55M
Q2 24
$7M
$7M
-$93M
Q3 24
$7M
$7M
-$94M
Q4 24
$5M
$5M
-$73M
Q1 25
$4M
$4M
-$63M
Q2 25
$17M
$17M
-$50M
Q3 25
$9M
$9M
-$76M
Q4 25
$45M
$45M
-$29M
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
6.1x
—
Q2 23
7.6x
—
Q3 23
21.8x
—
Q4 23
28.9x
—
Q1 24
30.7x
—
Q2 24
33.2x
—
Q3 24
33.3x
—
Q4 24
38.1x
—
Q1 25
47.5x
—
Q2 25
33.4x
—
Q3 25
31.1x
—
Q4 25
14.6x
—
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
-$44M
-$59M
Q2 23
$20M
-$8M
Q3 23
-$106K
-$20M
Q4 23
-$20M
-$34M
Q1 24
-$42M
-$66M
Q2 24
-$29M
-$49M
Q3 24
-$29M
-$48M
Q4 24
-$8M
-$24M
Q1 25
-$12M
-$22M
Q2 25
-$32M
-$46M
Q3 25
-$53M
-$62M
Q4 25
-$35M
-$45M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$15M
Q2 23
$27M
Q3 23
$20M
Q4 23
$14M
Q1 24
$24M
Q2 24
$20M
Q3 24
$19M
Q4 24
$16M
Q1 25
$11M
Q2 25
$13M
Q3 25
$9M
Q4 25
$10M
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
-96.1%
-15.9%
Q2 23
-78.1%
+13.1%
Q3 23
-93.5%
-3.4%
Q4 23
-57.4%
+26.8%
Q1 24
-18.4%
-15.9%
Q2 24
-27.2%
+64.0%
Q3 24
-1.4%
+62.9%
Q4 24
-45.0%
+3.4%
Q1 25
-57.5%
+3.2%
Q2 25
+133.3%
-33.8%
Q3 25
+37.6%
-14.9%
Q4 25
+788.2%
-5.6%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$15M
126.9%
Q2 23
$0
0.0%
Q3 23
$16M
240.4%
Q4 23
$16M
179.2%
Q1 24
$17M
174.9%
Q2 24
$0
0.0%
Q3 24
$0
0.0%
Q4 24
$15M
301.5%
Q1 25
$15M
349.1%
Q2 25
$14M
83.2%
Q3 25
$14M
155.2%
Q4 25
$13M
28.8%
marketcaparena.com
OpEx Breakdown
R&D
G&A
S&M
SG&A
Quarter
R&D
G&A
S&M
SG&A
Q1 23
$53M
$15M
$4M
—
Q2 23
$36M
$16M
$4M
—
Q3 23
$38M
$14M
$3M
—
Q4 23
$49M
$16M
$3M
—
Q1 24
$39M
$17M
$3M
—
Q2 24
$41M
$20M
$3M
—
Q3 24
$41M
$19M
$3M
—
Q4 24
$46M
$16M
$3M
—
Q1 25
$42M
$16M
$3M
—
Q2 25
$39M
$19M
$3M
—
Q3 25
$55M
$22M
$3M
—
Q4 25
$50M
—
—
$17M
marketcaparena.com
Revenue Segments
License
Milestone Payments
Research Fees
Quarter
License
Milestone Payments
Research Fees
Q1 23
$372K
$1M
$11M
Q2 23
$226K
—
$10M
Q3 23
$186K
—
$6M
Q4 23
$185K
$250K
$9M
Q1 24
$180K
—
$10M
Q2 24
$370K
$2M
$5M
Q3 24
$218K
—
$6M
Q1 25
$167K
—
$4M
Q2 25
$10M
—
$7M
Q3 25
$138K
—
$9M
Q4 25
$36M
—
$8M
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$193M
$603M
$796M
Q2 23
$180M
$616M
$796M
Q3 23
$172M
$613M
$786M
Q4 23
$133M
$627M
$761M
Q1 24
$124M
$574M
$698M
Q2 24
$148M
$522M
$670M
Q3 24
$127M
$516M
$643M
Q4 24
$156M
$469M
$626M
Q1 25
$159M
$446M
$605M
Q2 25
$92M
$461M
$553M
Q3 25
$83M
$413M
$496M
Q4 25
$155M
$405M
$560M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
288M
-4.5%
Q2 23
289M
+0.4%
Q3 23
289M
+0.2%
Q4 23
291M
+0.5%
Q1 24
293M
+0.6%
Q2 24
294M
+0.5%
Q3 24
295M
+0.2%
Q4 24
295M
-0.1%
Q1 25
298M
+1.1%
Q2 25
299M
+0.3%
Q3 25
299M
+0.1%
Q4 25
299M
-0.1%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 18
—
—
FY 19
—
—
FY 20
$1M
206
FY 21
$938K
400
FY 22
$981K
495
FY 23
$65K
586
FY 24
$48K
600
FY 25
$134K
562
marketcaparena.com